Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib
BiotechTV - News
00:00
Expanding ITK work: oncology and rare diseases
Richard discusses interest in solid tumors, updates on the ALPS study, and plans for next‑generation ITK programs.
Play episode from 23:47
Transcript
